The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease
Open accessAbstract
Recent studies indicate that oxysterols, which are ligands for the nuclear hormone liver X receptors (LXR), decrease amyloid beta (Abeta) secretion in vitro. The effect was attributed primarily to the ATP-binding cassette transporter A1 (ABCA1) transcriptionally up-regulated by ligand-activated LXRs. We now examined the effect of the synthetic LXR ligand T0901317, which can be used in vivo, on Abeta production in vitro and in APP23 transgenic mice. T0901317 applied to a variety of in vitro models, including immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons caused a concentration-dependent decrease in Abeta secretion, and this effect was increased by the addition of apolipoprotein A-I. The inhibition of Abeta production by T0901317 was cell-type specific, being more prominent in primary neurons than in non-neuronal cells. Tangier fibroblasts lacking a functional ABCA1 secreted more Abeta than control fibroblasts, thus demonstrating the role of ABCA1 in amyloid precursor protein (APP) processing and Abeta generation. T0901317 treatment of 11-week-old APP23 mice for 6 days showed a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)beta- to sAPPalpha-cleavage products. Most importantly, the treatment caused a statistically significant reduction in the levels of soluble Abeta40 and of Abeta42 in the brain these mice. Our experiments demonstrate that T0901317 decreases amyloidogenic processing of APP in vitro and in vivo, thus supporting the search for potent and specific LXR ligands with properties allowing therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“dosing of APP transgenic mice with LXR agonists, which increase murine CNS apoE levels, also decrease A levels (Koldamova et al., 2005;Burns et al., 2006;Riddell et al., 2007).”
From Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels (2008) · cites this paper as Koldamova et al., 2005
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Koldamova et al. and Sun et al. reported that ABCA1 induction decreases Aβ levels in cells by inhibiting both β- and γ-cleavage of APP [62-64].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 gene ablation in mice decreased APOE lipidation and levels and increased Aβ accumulation in APP transgenic mouse models.”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonists have been shown to decrease A deposition in the brain while modestly increasing apoE expression (Koldamova et al., 2005;Zelcer et al., 2007;Fitz et al., 2010).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Koldamova et al., 2005
Experimental — accuracy not yet measured
In the citing paper
“Interestingly, several genes expressed in the liver including liver X receptors (LXRs) have been suggested as potential therapeutic targets for AD [189–191].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationRole of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J. C., Li, L., Lustig, K. D., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,303
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Cited by
Sorted by citations
Items 201–282 of 282
Huang, C., & Zhang, Y. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101131400228 · Cited by 14
Liver X receptors: A therapeutic target in demyelinating disorders
Richartz, J., Yam, S. C., Zhan, N., Schepers, M., Tiane, A., Mulder, M. T., Wens, I., & Vanmierlo, T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107861 · Cited by 12
Wongwan, T., Kittayaruksakul, S., Asavapanumas, N., Chatsudthipong, V., & Soodvilai, S. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2033-8 · Cited by 12
Ishida, E., Hashimoto, K., Okada, S., Satoh, T., Yamada, M., & Mori, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054901 · Cited by 12
28-Homobrassinolide: a novel oxysterol transactivating LXR gene expression
Premalatha, R., Srikumar, K., Vijayalaksmi, D., Gali, N. K., & Mathur, P. P. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3632-5 · Cited by 12
Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats
Wang, S., Wen, P. H., & Wood, S. J. (2016) · F1000Research · doi:10.12688/f1000research.7868.2 · Cited by 11
Tice, C. M., Noto, P. B., Fan, K. Y., Zhao, W. L., Lotesta, S. D., Dong, C., Marcus, A. P., Zheng, Y., Chen, G., Wu, Z., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.089 · Cited by 12
Ban, S. Y., Nam, Y., Do, T. T., Kim, B., Shin, S. J., Nguyen, M. T. T., Kim, J., Moon, M., & Park, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117895 · Cited by 11
Apoptotic Cell Clearance and Its Role in the Origin and Resolution of Chronic Inflammation
Muñoz, L. E., Berens, C., Lauber, K., Gaipl, U. S., & i, M. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00139 · Cited by 10
Shan, X., Li, D., Yin, H., Tao, W., Zhou, L., Gao, Y. W., Xing, C., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031207 · Cited by 8
Zhu, M., Jia, L., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210411 · Cited by 9
Niacin, an Old Drug, has New Effects on Central Nervous System Disease
Chen, J., & Chopp, M. (2010) · The Open Drug Discovery Journal · Cited by 9
Goel, D., Faruq, M., Nazir, S. S., Kaushik, P., Parvez, S., & Vohora, D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70007 · Cited by 8
Allopregnanolone as a Therapeutic to Regenerate the Degenerated Brain
Hernandez, G. D., & Brinton, R. D. (2019) · ISGE series · doi:10.1007/978-3-030-11355-1_7 · Cited by 7
The N-Terminus of Human Sulfotransferase 2B1b─a Sterol-Sensing Allosteric Site
Cook, I. T., & Leyh, T. S. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00740 · Cited by 8
Zhang, J., Zhang, J., & Li, Y. (2016) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-016-0249-4 · Cited by 7
Sandoval-Hernández, A. G., Contreras-Zarate, M. J., Jaramillo, J., & Arboleda, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-40764-7_14 · Cited by 7
Martins, G. L., Ferreira, C. N., Palotás, A., Rocha, N. P., & Reis, H. J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327215245 · Cited by 6
Single-cell multi-region dissection of brain vasculature in Alzheimer’s DiseasePreprint
Sun, N., Akay, L. A., Murdock, M. H., Park, Y., Bubnys, A., Galani, K., Mathys, H., Jiang, X., Ng, A. P., Bennett, D. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.09.479797 · Cited by 6
Pharmacological Activation of LXRs Decreases Amyloid-β Levels in Niemann-Pick Type C Model Cells
Štefulj, J., Perić, M., Malnar, M., Košiček, M., Schweinzer, C., Živković, J., Scholler, M., Panzenboeck, U., & Hecimovic, S. K. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101131400224 · Cited by 5
Li, M., Yang, J., Cheng, O., Peng, Z., Luo, Y., Ran, D., Yang, Y., Xiang, P., Huang, H., Tan, X., et al. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622321998139 · Cited by 6
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 5
Detoxification and age-related neurodegenerative diseases: Correlation and therapeutic potential
Yan, Y., Maisenbacher, M., Huang, C., & Fan, S. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107849 · Cited by 6
The LXR/RXR Approaches in Alzheimer’s Disease: Is the Blood-Bra in Barrier the Forgotten Partner?
Fenart, P. C. L. (2013) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000e131 · Cited by 4
Cocks, G. D., Wilde, J. I., Graham, S. J., Bousgouni, V., Virley, D. J., Lovestone, S., & Richardson, J. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1266 · Cited by 4
No association of genetic variants of liver X receptor‐β with alzheimer's disease risk
Rodríguez‐Rodríguez, E., Llorca, J., Mateo, I., Infante, J., Sánchez‐Quintana, C., García‐Gorostiaga, I., Fernández‐Viadero, C., Peña, N., Berciano, J., & Combarros, O. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30652 · Cited by 4
Plasma Amyloid-β in Patients with Tangier Disease
Shahim, P., Bochem, A. E., Mattsson, N., Lautner, R., Blennow, K., Hovingh, G. K., Motazacker, M. M., & Zetterberg, H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122425 · Cited by 3
Arifuzzaman, S., Labu, Z. K., Harun‐Or‐Rashid, M., Laboni, F. R., Khatun, M. R., Ali, M. S., Hossain, S., & Chowdhury, N. S. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2960 · Cited by 3
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Alzheimer Disease and Metabolism: Role of Cholesterol and Membrane Fluidity
Genaro, G., Fermin, P., Luis, J., Miguel, A., Irma, E., Anguiano, A., Torres-Sánchez, E. D., Eddic, W., Jose, A., Genaro, E., et al. (2013) · InTech eBooks · doi:10.5772/54091 · Cited by 3
Xue, X.-H., Wang, N., Lin, Y., Zhao, G., Fang, L., Murong, S.-X., & Wu, Z. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000160954 · Cited by 3
Štefulj, J., Panzenboeck, U., Hof, P. R., & Šimić, G. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0136-z · Cited by 3
Cholesterol Trafficking in the Brain
Lütjohann, D., Vanmierlo, T., & Mulder, M. T. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_5 · Cited by 2
Nuclear Receptor Regulation of Osteoclast and Bone Remodeling
Jin, Z., Li, X., & Wan, Y. (2015) · Cited by 2
Huttunen, H. J., & Kovacs, D. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_6 · Cited by 2
Singh, M., Yu, J., Vanmierlo, T., Mulder, M. T., Paul, S. M., & Cashikar, A. G. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119506 · Cited by 1
Gomes‐Bispo, A., Cardoso, C. L., Afonso, C., Lourenço, H. M., Pedro, S., Moniz, P., & Bandarra, N. M. (2026) · Marine Drugs · doi:10.3390/md24060197 · Cited by 1
Saravanan, J., Easwaran, V., Selvaraj, D., Gunasekaran, V., Soumya, V., Thiruselvi, M., Prasanth, M. L., Singh, S., Ellaiyarasu, C., Rai, P. K., et al. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104108 · Cited by 1
In-silico Targets in Neurodegenerative Disorders
Nagy, A. V., & Polgár, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-6920-9_22 · Cited by 1
Searcy, J. L. (2009) · UKnowledge (University of Kentucky) · Cited by 1
Wang, L., Qian, H., & Wang, L. (2018) · Journal of Biology and Life Science · doi:10.5296/jbls.v9i1.12474 · Cited by 1
Role of Impaired ABC Transporters in Alzheimer’s Disease
Haque, M., Rather, G. A., Siddiqui, E. M., Jahan, S., Khan, A., Makeen, H. A., Alexiou, A. T., & Ashraf, G. M. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_13 · Cited by 1
Laham, M. S., Ackerman-Berrier, M. S., Alam, F., Turner, S., Velma, G. R., Penton, C., Musku, S. R., Rana, M., Thulasingam, S., Anandhan, A., et al. (2025) · eLife · doi:10.1101/2025.09.12.675753 · Cited by 1
Laham, M. S., Ackerman-Berrier, M. S., Alam, F., Turner, S., Velma, G. R., Penton, C., Musku, S. R., Rana, M., Kumar, S., Anandhan, A., et al. (2025) · eLife · doi:10.7554/elife.109146.1 · Cited by 1
Tierexperimentelle Behandlungsversuche der Charcot-Marie-Tooth-Erkrankung 1A
Weiss, B. G. (2014) · doi:10.53846/goediss-4385 · Cited by 1
Inhibition of Advanced Prostate Cancer by Androgens and Liver X Receptor Agonists
Chuu, C., Lin, H., Lin, C., Huo, C., & Su, L. (2011) · InTech eBooks · doi:10.5772/25334
Apolipoproteins E and C1 in the brain: role in Alzheimer's disease
Abildayeva, K. (2006) · Research Publications (Maastricht University) · doi:10.26481/dis.20061220ka
Brain sterol metabolism : modulating Alzheimer’s disease
Vanmierlo, T. (2010) · Research Publications (Maastricht University) · doi:10.26481/dis.20100930tv
Recherche de déterminants génétiques des phénotypes associés au syndrome métabolique en population
Legry, V. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Nuclear receptor functions in the central nervous system : Clues from knockout mice
Andersson, S. (2006) · Figshare
Non‐amyloid Approaches To Alzheimer's Disease
Veng, L., Savage, M. J., Barrow, J. C., & Zerbinatti, C. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc253
Jakobsson, T. (2011) · Figshare
Cholesterol: nieuw therapeutisch target bij de ziekte van Alzheimer?
Mulder, M. T., & van Mierlo, T. (2007) · Neuropraxis · doi:10.1007/bf03079128
Taira Wada, Hong Soon Kang, Martin Angers, Haibiao Gong, Shikha Bhatia, Shaheen Khadem,
Ren, S., Ellis, E. C. S., Strom, S. C., Jetten, A. M., & Xie, W. (2007)
Rodriguez, G. A. (2014) · DigitalGeorgetown (Georgetown University Library)
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Carter, A. B. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
TRAFFICKING OF ALPHA SECRETASE ADAM10: NEW INSIGHTS INTO THE MOLECULAR MECHANISM OF MODULATION
Saraceno, C. (2012) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/saraceno-claudia_phd2012-02-08
AXL receptor tyrosine kinase regulates Apolipoprotein E expression
Zhao, W. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0372324
Talukdar, S. (2006) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.2424
Transcriptional and Posttranscriptional Control of Cholesterol Homeostasis by Liver X ReceptorsPreprint
Ontonoz, P. T. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010702 · Cited by 47
Therapeutic effect of TO901317 on 6-OHDA-induced Parkinson rats in vitro and in vivoPreprint
Li, M., Yang, J., Cheng, O., Peng, Z., Luo, Y., Ran, D., Yang, Y., Xiang, P., Huang, H., Tan, X., et al. (2020) · doi:10.21203/rs.3.rs-15406/v1
Rôle du cholestérol et des récepteurs nucléaires LXRs dans le cancer de la prostate
Pommier, A. (2010) · theses.fr (ABES) · doi:10.70675/0c05694fzc641z454cz8ea3z1193cb115d99
Marques, R. B. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-06122021-121359
Therapeutic effect of TO901317 on 6-OHDA-induced Parkinson rats in vitro and in vivoPreprint
Li, M., Yang, J., Cheng, O., Peng, Z., Luo, Y., Ran, D., Yang, Y., Xiang, P., Huang, H., Tan, X., et al. (2020) · doi:10.21203/rs.3.rs-15406/v2
Li, M., Yang, J., Cheng, O., Peng, Z., Luo, Y., Ran, D., Yang, Y., Xiang, P., Huang, H., Tan, X., et al. (2020) · doi:10.21203/rs.3.rs-15406/v3
Han, S., Yuan, X., Zhao, F., Manyande, A., Gao, F., Wang, J., Zhang, W., & Tian, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2967465/v1
Rahimpour, A., Shahbazi, B., & Mafakher, L. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2313166
Arifuzzaman, S., Harun‐Or‐Rashid, M., Laboni, F. R., Khatun, M. R., & Chowdhury, N. S. (2025) · Computational Toxicology · doi:10.1016/j.comtox.2025.100361
Laham, M. S., Ackerman-Berrier, M. S., Alam, F., Turner, S., Velma, G. R., Penton, C., Musku, S. R., Rana, M., Thulasingam, S., Anandhan, A., et al. (2025) · eLife · doi:10.7554/elife.109146
Fredriksen, K., Joshi, S. S., Chang, A., & Li, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.16.694774
Kiriyama, Y., Nakatsuma, A., Tokumaru, H., Sadamoto, H., & Nochi, H. (2026) · Metabolites · doi:10.3390/metabo16030189
Laham, M. S., Ackerman-Berrier, M. S., Alam, F., Turner, S., Velma, G. R., Penton, C., Musku, S. R., Rana, M., Thulasingam, S., Anandhan, A., et al. (2026) · eLife · doi:10.7554/elife.109146.2
Li, D., Zhang, Y., Wang, R., Jin, L., Cui, X., Hong, J.-S., Li, S., Zhao, J., & Guo, Y. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00899
Hosseinzadeh, P., Mohammadipour, A., Sajjadi, S. M., Hosseini, M., & Rastegar-Moghaddam, S. H. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45428
BindingDB (2009) · UC San Diego · doi:10.7270/q21j99b2
BindingDB Entry 50018264: Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.
BindingDB (2024) · UC San Diego · doi:10.7270/q27p93md
BindingDB Entry 50000120: Polypharmacology of N
BindingDB (2019) · UC San Diego · doi:10.7270/q2xk8hqh
Metadata
- Authors
- Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S.
- Affiliations
- University of Pittsburgh (US)
- Novartis Institutes for BioMedical Research (CH)
- University of Münster (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Koldamova, Radosveta P.
- Lefterov, Iliya M.
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 6
- Pages
- 4079-4088
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1996457468
- Cited by
- 279
- References
- 55
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 17 · 2013: 22 · 2012: 15
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health
- National Institute on Aging (AG 18558, AG 23304, R03AG023304)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- liver X receptor, T0901317, amyloid-beta, Alzheimer's disease, ABCA1, oxysterols, APP processing, APP23 transgenic mice, apolipoprotein A-I, soluble APP alpha, cell type specificity, LXR ligands
- MeSH terms
- Liver X Receptors, Benzenesulfonamides, Alzheimer Disease, Animals, Anticholesteremic Agents, Brain, Cloning, Molecular, Disease Models, Animal, DNA-Binding Proteins, Enzyme-Linked Immunosorbent Assay, Fibroblasts, Fluorocarbons, Humans, Hydrocarbons, Fluorinated, Ligands, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Protein Binding, Sulfonamides, Time Factors, Transcription, Genetic, Transfection, Blotting, Western, Up-Regulation, Amyloid beta-Protein Precursor, Apolipoprotein A-I, DNA, Complementary, Simplexvirus, Receptors, Cytoplasmic and Nuclear, Immunoprecipitation, Mice, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
